Abstract:For adult patients diagnosed with relapsed B cell-ALL (B-ALL), there have been significant improvements in available treatment options following the FDA approval of novel cellular and immunotherapy approaches – blinatumomab, chimeric antigen receptor (CAR) T therapy, and inotuzumab. For the last several years, research has focused on gaining a better understanding of the effects of specific disease and patient characteristics on long-term outcomes with each of the FDA-approved agents. In combination with the better prevention and management of unique, treatment-specific toxicities, providers can now select the best available treatment option for each individual patient diagnosed with relapsed, adult B-ALL needing therapy. This has allowed more patients to proceed to consolidative hematopoietic stem cell transplant (HSCT), and long-term data has even brought into question the need for HSCT for long-term durable remission for all patients. However, with the adoption of blinatumomab, CAR T therapy, and inotuzumab in front-line treatment regimens, it remains unclear what effects this will have on patients with relapsed B-ALL following exposure to these novel cellular and immunotherapy therapies. Unlike B-ALL, similar advances have unfortunately not yet been realized in T cell-ALL (T-ALL). Currently, new therapeutic approaches are underway to utilize similar targeting strategies that have been successful in B-ALL – monoclonal antibodies, bispecific T-cell engagers (BiTE), and CAR T therapy. Like B-ALL, the only existing approved therapy for relapsed T-ALL, nelarabine, is now used in the upfront treatment setting potentially limiting its utility in relapsed disease. Over the next several years, the hope is for patients diagnosed with T-ALL to experience the drastic improvement in outcomes as has been seen for patients diagnosed with B-ALL over the last decade.

Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia

Immunotherapy in first line treatment of adult acute lymphoblastic leukemia

Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy

Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms

Recent advances and novel treatment paradigms in acute lymphocytic leukemia

Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium

Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens

Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives

Novel Agents and Biomarkers for Acute Lymphoid Leukemia

Acute lymphoblastic leukemia: a comprehensive review and 2017 update

Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia

[New and traditional directions in the biology and management of childhood acute lymphoblastic leukemia]

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients

Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia

Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012

[Strategy for treatment of acute lymphoblastic leukemia]

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia

Predicting relapse in acute lymphoblastic leukemia

Recent updates for antibody therapy for acute lymphoblastic leukemia

SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia